Ultromics receives FDA Clearance for a first-of-kind solution in Echocardiography to help clinicians diagnose disease

"EchoGo Pro is an AI service for automated identification of coronary artery disease

- FDA gives 510(K) clearance for EchoGo Pro, expanding the use of Ultromics' EchoGo service to support clinicians diagnosing coronary artery disease

- Every year in the U.S. over 800,000 people die from heart disease - accounting for 1 in every 3 deaths - around 160,000 are under the age of 65.

- Coronary artery disease (CAD) is the most common form of heart disease and affects over 16.5 million people over the age of 20.

- by 2035, the economic burden of CAD will be in the region of $749 billion in the U.S alone

OXFORD, England, Jan. 6, 2021 /PRNewswire/ -- A world-first, AI powered, outcomes-driven, decision support tool – EchoGo Pro, has been cleared by the FDA and is now available to clinicians across the U.S. EchoGo Pro was trialed and validated in the UK and US, improving the diagnostic accuracy of clinicians for Coronary Artery Disease (CAD), the most common form of heart disease and leading cause of death in the U.S.

CAD indications can be subtle. Misdiagnosis happens with one in five patients potentially resulting in poor treatment and outcomes, which is compounded by the subjectivity of interpretation between clinicians. With the use of EchoGo Pro clinicians have additional insights, derived from AI models trained on large datasets in Oxford, which are valuable in the assessment of CAD, improving disease prediction and supporting more accurate diagnosis. This should lead to earlier suitable interventions, reducing cardiac events and improving patient care.

Dr Ross Upton, founder and CEO of Ultromics, comments: "Coronary artery disease is a huge global burden, affecting tens of millions of peoples' lives worldwide. Heart disease is the biggest killer globally and this number is increasing daily. Our goal is to help doctors detect CAD more accurately, improving patient outcomes and saving lives."..." Lire la suite